Presentation TCT 2016 Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS? Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy November 01, 2016
Presentation TCT 2016 Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure? Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White November 01, 2016
Presentation TCT 2016 Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers November 01, 2016
Presentation TCT 2016 Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant November 01, 2016
Presentation TCT 2016 Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad November 01, 2016
Presentation TCT 2016 Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx October 30, 2016
Presentation Fellows 2016 How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Presenter: Roxana Mehran April 15, 2016
Presentation TCT 2015 TCT 77: Risk and Benefits of Triple Therapy in Patients Undergoing Percutaneous Coronary Stent Implantation Requiring Chronic Oral Anticoagulation A Meta-analysis of 12 Trials Presenter: Lisa K. Jennings, Neal S. Kleiman, Lucia Barbieri October 13, 2015
Presentation TCT 2015 PCI and Atrial Fibrillation Anticoagulation: Triple or Dual Therapy? Presenter: George D. Dangas, Paul A. Gurbel, C. Michael Gibson October 13, 2015
Presentation Use and Outcomes of Triple Therapy Among Older Patients With Acute MI and A-fib Presenter: Connie N. Hess August 03, 2015
Presentation Fellows 2015 How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Presenter: Manish A. Parikh, Roxana Mehran May 15, 2015
Presentation Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation Presenter: K.A. Fiedler April 22, 2015
Presentation TCT 2014 TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang September 15, 2014
Presentation TCT 2014 TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis September 15, 2014
Presentation TCT 2014 When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White September 15, 2014
Presentation TCT 2014 Reversal of Factor Xa Inhibition Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Lisa K. Jennings September 15, 2014
Presentation TCT 2014 Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz September 15, 2014
Presentation TCT 2014 Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger September 15, 2014
Presentation TCT 2014 Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson September 15, 2014
Presentation TCT 2014 Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri September 15, 2014